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This paper reviews both the evidence that supports the characterization of depression as
an inflammatory disorder and the different biochemical mechanisms that have been pos-
tulated for the connection between inflammation and depression. This association offers
credible explanation for the short term efficacy of antidepressants, which have short term
anti-inflammatory effects. Evidence for those anti-inflammatory effects is discussed. Evi-
dence of the contrary long-term effects of antidepressants, which increase rather than
decrease inflammation, is also reviewed. It is argued that this increase in inflammation
would predict an increase in chronicity among depressed patients that have been treated
with antidepressants drugs, which has been noted in the literature. A brief discussion of
alternatives for decreasing inflammation, some of which have demonstrated efficacy in
ameliorating depression, is presented.
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DEPRESSIVE BEHAVIORS INVOLVE INFLAMMATION
The association between stress, systemic inflammation, and behav-
ioral signs of depression has been recognized for over a decade
(Raison et al., 2006; Capuron et al., 2008; Dantzer et al., 2011).
Depressed and anxious persons display elevations in blood lev-
els of inflammatory cytokines [Interleukin-6 (IL-6) and tumor
necrosis factor-α (TNF-α)] as well as other markers of an inflam-
matory state [e.g., C-reactive protein (CRP), soluble intracellular
adhesion molecule-1 (ICAM-1), and macrophage chemoattrac-
tant protein-1; Rajagopalan et al., 2001; Zorrilla et al., 2001;
Schiepers et al., 2005; Raison et al., 2006; Howren et al., 2009;
Dowlati et al., 2010], and given a social stressor, depressed individ-
uals exhibit greater elevations in inflammatory cytokines, such as
IL-6 (Pace et al., 2006). Depressed persons also exhibit lower levels
of anti-inflammatory cytokines (Li et al., 2011).
In addition to the findings for persons exhibiting behavioral
signs of depression, the immune system function of individuals
undergoing stress has been evaluated. In examining the leuko-
cytes from individuals who reported loneliness, Cole et al. (2007,
2011) found increased transcriptional activity of Nuclear Factor-
κB (NF-κB), a marker of inflammatory activation. The spouses
of Alzheimer patients and caregivers for cancer patients are char-
acterized by high levels of inflammatory cytokines such as IL-6
(Kiecolt-Glaser et al., 2003; von Kanel et al., 2006) and higher
levels of NF-κB activity (Miller et al., 2008). Persons who are
under stress at work exhibit elevations in ICAM-1, inflammatory
cytokines, and acute phase proteins such as fibrinogen (von Kanel
et al., 2001; Steptoe et al., 2003; Ramachandruni et al., 2004; Hong
et al., 2006).
INVESTIGATING CAUSAL CONNECTIONS
Relatively early in these investigations, Maier and Watkins (1998)
advanced the hypothesis that undergoing psychological stress
or provoking inflammation in the periphery induces an equiv-
alent state of systemic inflammation. According to Maier and
Watkins, systemic inflammation correlates with changes in the
brain. Regardless of the initiating event, whether an infection or
a psychological stressor, behavioral manifestations of depression
emerge that are driven by synonymous changes in the brain. Maier
and Watkins speculated that during evolution, an immune system
for fighting pathogens emerged first. When multi-celled organisms
needed a mechanism for responding to an external psychological
threat, the body recruited the already existing immune system
for responding to external threat. Similar ideas were proposed
by Maes et al. (1999). With regard to the evolutionary connec-
tion between psychological stressors and inflammatory activation,
Pace et al. (2012) have suggested that given a psychological threat,
such as attack by a predator, preparing the immune system to fight
infection resulting from a predatory attack could be adaptive.
Manipulating psychological stress
Given the association between subjective distress and markers of
systematic inflammation, researchers investigated the direction of
a possible causal relationship. Learned helplessness is an animal
model of depression. To induce learned helplessness, researchers
subject animals to bouts of uncontrollable shock. The animal can-
not escape or avoid the shock. Subsequent to this stressor, the
animal appears depressed. The animal fails to drink sucrose, dis-
plays less locomotion, fails to explore new environments, and, even
when subsequently given an opportunity to avoid an aversive stim-
ulus, fails to escape or avoid. Animals subjected to helplessness
inductions also have elevated levels of IL-1, in their hippocampus
and hypothalamus (Maier and Watkins, 1998). Moreover, when
an antagonist for the IL-1 is placed in the hippocampi of animals
exposed to uncontrollable shock, the animal no longer exhibits
depressed behavior, and no longer fails to escape aversive stimuli
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(Maier and Watkins, 1995; Johnson et al., 2004; Koo and Duman,
2008; Arakawa et al., 2009). Thus, IL-1 in the hippocampus seems
to play a causal role in mediating behavioral manifestations of
depression.
Another way to make an animal exhibit signs of depression is
to expose the animal to repeated episodes of social defeat. After
exposure to rounds of social defeat the animal avoids other ani-
mals, displays reduced preference for sucrose, and appears more
depressed on tests such as the forced swim test and the tail sus-
pension test. Concomitant with behavioral signs of depression,
animals display elevation in inflammatory cytokines in plasma
(Merlot et al., 2004; Kinsey et al., 2007, 2008; Avitsur et al., 2009).
In addition to the work with animals showing that stressing
the animal will induce signs of systemic inflammation, there is
also experimental work in humans. Persons who are subjected to
laboratory stressors exhibit activation of NF-κB (Bierhaus et al.,
2003) as well as an increase in inflammatory cytokines such as
IL-6 in plasma (Pace et al., 2006). In those individuals who are
low on chronic stress, increases in NF-κB activity are correlated
with perceived intensity of the laboratory stressor (Wolf et al.,
2009). A study by Slavich et al. (2010) examined how a social
stressors inducing elevations in inflammatory cytokines changes
brain function. Following the social stressor, those with elevations
in the soluble receptor for TNF-α exhibited greater activation in
the dorsal anterior cingulate and the anterior insula, two areas
involved in processing negative affect.
Manipulating peripheral inflammation
Studies established that stressing the animal in various ways results
in behavioral manifestations of depression along with elevations in
inflammatory cytokines in brain and in plasma. The next question
was whether establishing systemic inflammation in the periphery
would result in behavioral manifestations of depression. Placing
lipopolysaccharide (LPS) molecules in the paw of a mouse is a reli-
able way to elevate cytokines in the blood stream without inducing
real tissue damage to the organism from the bacteria. Follow-
ing elevations in cytokines in the blood stream, the mice exhibit
a lack of preference for formerly preferred foods, low levels of
activity, more social avoidance, less exploration of novel environ-
ments, an increase in body temperature, and an increase in the
production of cortisol (Dantzer, 2001; Nadjar et al., 2005). Con-
comitant with the behavioral change, the following are observed:
an increase in the threshold for self-stimulation in the medial
forebrain bundle (Borowski et al., 1998), a diminution in activ-
ity in brain areas associated with positively motivated behavior
(Stone et al., 2007), an increase in activation as detected by eleva-
tions in FosB/∆FosB in areas of brain associated with depression
(viz., parts of the shell of the Nucleus Accumbens, bed nucleus
of the stria terminalis (BNST), and the central nucleus of the
amygdala; Frenois et al., 2007; Engler et al., 2011). Moreover,
IL-1 levels in brain (the hippocampus and hypothalamus) are ele-
vated. Again, when IL-1 antagonists are placed into the brain, the
depressed behaviors disappear, although it is noted that timing for
the administration of the IL-1 receptor antagonist (IL-1ra) and
placement of the IL-1ra can alter the parameters of the response
to LPS that are abrogated (Bluthe et al., 1995; Konsman et al.,
2008).
In addition to the animal work, similar work in humans is
available. Several of these studies observed random-assignment
to either peripheral induction of systemic inflammation or to a
control condition. Those who received endotoxin administration
displayed impairment in memory which correlated with inflam-
matory cytokine levels (Reichenberg et al., 2001; Krabbe et al.,
2005) and an elevation in negative mood which correlated with
cytokine levels (Reichenberg et al., 2001). Vaccinating people with
typhoid proteins is another reliable way to elevate inflammatory
cytokines. Vaccinated individuals displayed elevations in negative
mood which correlate with IL-6 levels (Wright et al., 2005).
Peripheral inflammation does impact the brain
Since the brain is supposed to be impervious to the entry of
cytokines, the question of how cytokines in the periphery commu-
nicate with brain has been a subject of inquiry. Several mechanisms
have emerged. First, the sensory vagus nerve, which has receptors
for IL-1 and prostaglandins (Ek et al., 1998), responds to local
inflammation and results in activation in the Nucleus Tractus
Solitarius of the medulla which relays information to its projec-
tion areas (the parabrachial, paraventricular and supraoptic nuclei
and ventromedial preoptic area of the hypothalamus, the central
amygdala, and the BNST; Dantzer et al., 2000, 2007; Goehler et al.,
2000; Konsman et al., 2000). Second, activated leukocytes in circu-
lation can communicate with brain tissue at areas where the blood
brain barrier is weaker: the choroid plexus and circumventricular
organs, such as the median eminence, the organum vasculosum
lamina terminalis, the subfornical organ, and the area postrema. In
these areas, the junctions between the endothelial cells lining blood
vessels are less tight and allow for diffusion of cytokines (Konsman
et al., 1999; Dantzer et al., 2000). Moreover, inflammatory proteins
in plasma, such as monocyte chemoattractive protein-1 (MCP-
1), can weaken the blood brain barrier (Stamatovic et al., 2005).
Finally, there are active transport molecules on endothelial cells
that allow for cytokines to be transported across the blood brain
barrier (Dantzer et al., 2007; Shelton and Miller, 2010). Once in
the CNS, the cytokines activate the microglia. When microglia get
activated, they release MCP-1 which will bring other white blood
cells to the brain (Shelton and Miller, 2010).
Forces that can restrain systemic inflammation
The body does have mechanisms for curtailing an inflammatory
response following clearance of a pathogen. Following activation
in response to a pathogen, T regulatory cells (Tregs) are also
differentiated. Tregs are identified by their surface expression of
CD25 and the expression of the transcription factor: FoxP3. Tregs
release IL-10 and transforming growth factor-β (TGF-β), which
are anti-inflammatory cytokines (Murphy, 2012).
Data supporting the hypothesis that stress will increase the level
of inflammatory cytokines has been presented. It is also the case
that a laboratory stressor will decrease the level of IL-10 (Buske-
Kirschbaum et al., 2007) as well as the number of circulating Tregs
(Freier et al., 2010). Lower levels of Tregs are also observed in
those who are chronically stressed as well. Stress will decrease the
number of circulating Tregs; will downregulate FoxP3, the tran-
scription factor for Treg differentiation; and decrease plasma levels
of IL-10 and TGF-β (Raison et al., 2010c).
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A protective role for IL-10 in preventing distress has been estab-
lished. Administration of IL-10 along with administration of LPS
prevents the emergence of behavioral signs of depression (Bluthe
et al., 1999). Mice have been genetically engineered to over-express
IL-10 display less anxiety, while IL-10 knock outs display greater
levels of anxiety and depressive behavior on a forced swim test,
although the impact of IL-10 is more pronounced in females
(Mesquita et al., 2008). In the human literature, under stressful
conditions, those persons with higher levels of IL-10 report less
anxiety (Maes et al., 1998). Following vaccination with an inflam-
matory antigen, optimistic persons maintain higher levels of IL-10
(Costanzo et al., 2004).
Others have attempted to increase T regulatory cells by vacci-
nating with antigens known to elicit a Tregs response. Vaccination
with a heat killed preparation of Mycobacterium vaccae will evoke
a Treg response (Rook and Lowry, 2008). Those who were vacci-
nated with M. vaccae report better quality of life (Dalbeth et al.,
2004; O’Brien et al., 2004).
OTHER CONSISTENT FINDINGS
Beyond the random-assignment controlled research, there are
other studies consistent with the hypothesis that systemic inflam-
mation is associated with depressive behaviors. Particular dis-
eases (metastatic melanoma and hepatitis virus C) are treated
with Interferon-α (IFN-α). IFN-α will induce systemic inflam-
mation. A significant number of persons (30–50%) undergoing
such treatment subsequently develop clinical depression (Raison
et al., 2009). In fact, in those being treated with IFN-α, feelings
of guilt and suicidal ideation are increased, not just malaise and
fatigue (Capuron et al., 2009).
In addition to the data on behavioral impact of IFN-α, several
conditions are associated with a rise in inflammatory cytokines.
Both obesity and sleep deprivation are associated with elevations
in blood levels of inflammatory cytokines (IL-1β, TNF-α). Both
these conditions are risk factors for depression (Irwin et al., 2006;
Shelton and Miller,2011). Metabolic syndrome,a state of increased
weight around the waist, is associated with high levels of IL-6 and
CRP and is also a risk factor for depression (Capuron et al., 2008).
Some of the human research has examined how systemic
inflammation alters brain function as observed through functional
magnetic resonance imaging. Administration of IFN-α induces
activation of the dorsal anterior cingulate-error detection area
(Capuron et al., 2005). Inoculation with typhoid proteins, which
increases systemic levels of IL-6, similarly enhances activity of the
insula and right anterior cingulate which correlate with subjective
fatigue and confusion (Harrison et al., 2009). Moreover, inoc-
ulation with typhoid proteins results in diminished control of
the subgenual anterior cingulate cortex by regulatory centers for
reward, emotion, and social processing, a phenomenon which is
correlated with levels of IL-6 (Harrison et al., 2009). In addition to
inducing changes in areas associated with error processing such as
the anterior cingulate cortex, systemic inflammation is correlated
with changes in dopaminergic system, the system which under-
girds motoric activity and motivation. Following typhoid protein
inoculation, levels of IL-6 correlate with altered activity in the
substantia nigra and behavioral measures of slower reaction times
(Brydon et al., 2008). A study by Eisenberger et al. (2011) also
noted changes in dopaminergic structures. LPS administration in
the periphery results in less activity in the ventral striatal area (the
brain’s reward area) in response to monetary reward.
INFLAMMATORY CYTOKINES MAY EXPLAIN DEXAMETHASONE
NON-SUPPRESSION
Another consistent finding in the literature is that the level of cor-
tisol hormone is often elevated in depressed individuals, although
30–50% of depressed individuals may not display elevations in
cortisol (Muller and Holsboer, 2006; Pace and Miller, 2009). Corti-
cotropin releasing hormone (CRH) from the parvocelluar neurons
in the paraventricular nucleus of the hypothalamus is the proxi-
mal cause of elevations in cortisol. With regard to regulation of this
system, given normal functioning, cortisol will act on receptors for
cortisol in the hippocampus. The hippocampus, through connec-
tions in the BNST, will then communicate with the paraventricular
nucleus of the hypothalamus to inhibit the CRH release. Moreover,
the BNST is probably more important in regulating CRH release
in situations of chronic stress (Sapolsky, 1985; Ulrich-Lai and Her-
man, 2009). This is the negative-feedback system for dampening a
response. But in depressed individuals, this inhibitory system does
not work well. The problem with CRH not being suppressible
in depressed individuals may be related to inflammatory states.
It has been demonstrated in fibroblast cells that inflammatory
cytokines will interfere with glucocorticoid receptors function,
although possible variation in cell types is acknowledged (Pariante
et al., 1999). Thus, inflammation may be the mechanism creating
resistance to control of the cortisol system in depressed individuals
(Pariante et al., 1999; Pace et al., 2007). Not only will inflammatory
cytokines interfere with regulation of cortisol release, but inflam-
matory cytokines are also associated with less circadian variation
in cortisol release (Raison et al., 2010a).
GENETIC RISK
Vulnerability to depression under stressful conditions is conferred
by various alleles associated with proteins of the immune sys-
tem. The short promoter in the gene for the serotonin transporter
has received a great deal of attention as a risk factor for depres-
sion (Lasky-Su et al., 2005). Interestingly, those carrying the short
promoter version of the serotonin transporter release more IL-6
relative to IL-10 given exposure to a laboratory stressor (Fredericks
et al., 2010). The less frequently expressed alleles for the serotonin
transporter are at increased risk for exhibiting depression given
exposure to IFN-α (Bull et al., 2009; Lotrich et al., 2009), although
the serotonin transporter gene interacted with alleles for IL-6 only
making a difference in those who carried the allele for the less
easily expressed IL-6 gene in the Bull et al. study. Particular alleles
for TNF-α and IL-1 are also associated with risk for depression or
severity of symptoms (Jun et al., 2003; Yu et al., 2003; Raison et al.,
2006; Traks et al., 2008). Thus, in looking for genetic vulnerability
to major depression, proteins of the immune system may be as or
more predictive than proteins associated with neurotransmitter
function.
QUESTIONS REMAIN
Questions about the hypothesis that inflammation has a critical
role in depression have been raised. The symptoms induced by
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cytokines versus a psychological stressor may only partially over-
lap. Clinically, Capuron et al. (2009) compared the phenomenon
emerging in those who are treated with IFN-αwith the symptoma-
tology in those who are depressed for other reasons. Psychomotor
retardation and weight loss predominated in the former whereas
guilt was more predominant in the latter. In those treated with
IFN-α, sickness behavior emerged immediately whereas depressive
symptoms emerged a month after treatment initiation (Capuron
and Miller, 2011). In terms of malleability, some interventions may
differentially affect sickness behaviors versus depressive behaviors.
For example, O’Connor et al. (2009a) administered an inhibitor of
indolamine 2,3 dioxygenase (IDO to be discussed later) along with
inflammatory cytokines. The IDO inhibitor precluded depressive
behaviors (more immobility on a forced swim test and tail suspen-
sion test) induced by cytokines while failing to affect locomotor
activity, weight change, or fever.
Subtle variations in the response to psychological stressors
versus systemic inflammation induced by infection are possible.
Immunological symptoms emerge in stages after exposure to a
stressor (Maier and Watkins, 2010). The response to cytokines
can vary as a function of dosage and will also emerge in stages
(Dantzer, 2004; Capuron and Miller, 2011). Moreover, there may
be subtypes of depression in which inflammation plays a lesser
role. However, the overlap between response to a psychological
stressor and response to a pathogen is well established.
STRESS AND SUPPRESSION OF SOME COMPARTMENTS OF THE
IMMUNE SYSTEM
The finding that depressed behaviors are associated with indi-
cators of systemic inflammation was surprising. During the late
1980s and 1990s, the field of psychoneuroimmunology was rapidly
developing. Animal work and human studies showed that stress
depresses many compartments of immune system function. Sem-
inal observations included the following: Epstein–Barr virus is
more likely to be reactivated in medical students during final exams
(Glaser et al., 1994). Wound healing is slower in dental students
during final exams and in Alzheimer patient caregivers (Kiecolt-
Glaser et al., 1995; Marucha et al., 1998). Stressed individuals,
such as caregivers of Alzheimer Disease patients, fail to develop
a robust antibody response to vaccination (Kiecolt-Glaser et al.,
1996; Glaser et al., 2000). Later, the findings that systemic inflam-
mation characterized depressed and stressed individuals emerged.
The idea that the body’s response to stress involved an immune
activation as well as suppression of some compartments of the
immune system seemed contradictory.
The immune system is complex and capable of making many
types of responses. A big division of the compartments of the
immune system is innate versus adaptive immunity. Innate immu-
nity includes those leukocytes that respond promiscuously,activat-
ing in response to many pathogens and other foreign molecules.
Many of the inflammatory cytokines are products of the innate
system. In contrast, the adaptive immune system refers to those
leukocytes (T and B lymphocytes) that respond to only one type
of molecule and whose responding takes a period of days to acti-
vate. Adaptive immunity is evoked with vaccination. A consensus
is beginning to emerge regarding the differential impact of stress
on the innate versus the adaptive immune systems. Stress reliably
decreases the adaptive immune system as well as decreasing natural
killer cell activity. In contrast to the adaptive system, stress acti-
vates the innate system, i.e., monocytes and macrophages which
release inflammatory cytokines (Maier and Watkins, 1998; Zorrilla
et al., 2001; Raison et al., 2006).
Blume et al. (2011) observed that few studies have measured
both immune system activation (as evidenced by inflammatory
cytokines) and immune system suppression (less proliferation of T
and B cells, attenuated Natural Killer Cell Cytotoxicity, lower levels
of wound healing) in the same study. However, there is evidence
that chronic activity of the innate immune system is associated
with less robust response from cells of the adaptive immune system
(Maier and Watkins, 1998; Blume et al., 2011). Indeed, exposure
of T cells to TNF-α, an inflammatory cytokine, will decrease T cell
proliferation and production of cytokines (Lee et al., 2008).
One of the early investigations in the literature on psychoneu-
roimmunology addressed the question of whether persons under-
going severe stress are more likely to “catch a cold.” The studies
showed that persons undergoing major stressors produced more
mucous and exhibited more symptoms after inoculation with a
flu virus (Cohen, 2005). However, the question of whether more
symptoms are reflective of greater activation or lesser activation of
the immune system is complicated. Cold symptoms (mucous pro-
duction, inflamed nasal passages) are phenomena reflecting innate
immune system activation. A recent study by Huang et al. (2011)
provided further clarification on which arms of the immune sys-
tem are activated or suppressed in those manifesting symptoms in
response to a cold virus. Huang et al., as in the earlier Cohen stud-
ies, inoculated research-participants with live influenza and then
tracked research-participant responses over time. Those remain-
ing asymptomatic had downregulated the NF-κB pathway of the
innate system. However, with regard to the adaptive immune sys-
tem, there was suggestion of a strong Th1 response to the virus in
those who remained asymptomatic. The Huang et al. study thus
demonstrated that activation of the innate immune system can
accompany a less vigorous response from the adaptive system.
THE IMPORTANCE OF CYTOKINES IN BRAIN MEDIATING
BEHAVIORAL CHANGES
Researchers have abrogated the behavioral changes in response to
LPS in the periphery or learned helplessness induction by placing
an antagonist to IL-1β into brain (Maier and Watkins, 1995; John-
son et al., 2004; Koo and Duman, 2008; Arakawa et al., 2009). These
findings imply that IL-1β, an inflammatory cytokine, induces
changes which eventually result in behavioral manifestations of
depression. Other researchers have investigated the downstream
changes associated with an increase in IL-1β that might operate as
more proximal factors in driving the behavioral manifestations of
depressed behavior. Discussion of downstream events subsequent
to an increase in IL-1βilluminates the significance of brain derived
neurotrophic factor (BDNF), a protein which has been featured in
explanations of the mechanisms behind the efficacy of antidepres-
sants, as well as the significance of IDO, which has been purported
to link to the serotonergic system.
Immunologists view inflammation as a mechanism for fight-
ing pathogens. Most immunology texts view the primary job of
leukocytes as providing protection against pathogens. However, a
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new role for cells of the immune system has been posited by Ziv
and Schwartz who have shown that activated leukocytes play a
vital role in maintaining the health of the brain (Schwartz and Ziv,
2008b). The “type of immune activation critically determines the
outcome” (Schwartz and Shechter, 2010a, p. 343). The emerging
view is that white blood cells, if activated along non-inflammatory
pathways, can contribute to brain health and result in behavioral
resilience in the face of external stressors. Growth factors, such as
BDNF, are featured in the health-promoting activation research as
well. In the literature on brain health, there has also been a focus
on systemic immunological factors that influence the behavior of
brain leukocytes. After examining specifics regarding the state of
brain inflammation, a discussion of how the immune system can
support brain health and behavioral resilience is presented.
THE INFLAMMATORY PATHWAY
Microglia are resident white blood cells in brain. They are essen-
tially the brain’s resident macrophages, which can engulf and
destroy pathogens. When microglia detect LPS or the animal
is stressed, the microglia become activated and can release the
inflammatory cytokines: IL-1, TNF-α, and IL-6 (Monje et al., 2003;
Perry et al., 2003; Blandino et al., 2006; Schwartz and Ziv, 2008b;
Ekdahl et al., 2009; Molina-Holgado and Molina-Holgado, 2010;
Tynan et al., 2010). This is effectively an inflammatory pathway.
Blocking microglia’s inflammatory response subsequent to LPS
administration will abrogate the emergence of depressed behav-
iors. Henry et al. (2008) showed that if a drug (minocycline), which
prevents activation of microglia, is given prior to LPS administra-
tion, then depressive behavior (decreased preference for sucrose)
is precluded. Moreover, in the Henry et al. study, minocycline pre-
vented the rise in inflammatory cytokines (IL-1β and IL-6) in the
hippocampus as well as attenuating the increased expression of
IDO (which is discussed the next section).
Subsequent research has offered clues into phenomenon in
brain that occur in response to inflammatory cytokines such as
IL-1β that might constitute more proximal causes for changes in
behavior. Koo and Duman (2008) showed that pretreatment with
an IL-1β inhibitor will block the emergence of depressive behav-
iors and prevent the decrement in neurogenesis in response to
stress. (The significance of decrements in neurogenesis in medi-
ating depressive behaviors will be discussed in a later section.)
Downstream of IL-1β is activation of the transcription factor, NF-
κB. The changes in behavior induced by IL-1β can be abrogated
by blocking the activity of the transcription factor NF-κB, whose
activity is increased by IL-1β (Nadjar et al., 2005; Koo et al., 2010).
NF-κB serves to further enhance inflammation.
The indolamine 2,3 dioxygenase connection
Indolamnine 2,3 dioxygenase has been a focus of much discussion
in the literature on inflammation mediating depressive behavior.
This enzyme is present in macrophages, as well as other cell types,
and operates when a macrophage is activated. It is also active
in brain under conditions of chronic inflammation. IDO con-
verts tryptophan to kynurenine and thereby depletes the local
environment of tryptophan. Tryptophan is the substrate for the
production of serotonin (Miller, 2009).
Some have suggested a causal role for the IDO enzyme in the
depressive behaviors associated with inflammation (Miller, 2009;
Raison et al., 2010b). The strongest evidence for IDO playing a
causal role in LPS or bacille Calmette–Guréin induced depres-
sion is the finding that inflammation fails to induce depressed
behaviors in mice lacking the indolamine 2,3 dixoxygenase gene
or when an inhibitor of the enzyme is given (O’Connor et al.,
2009a,b; Raison et al., 2010b). Interestingly, inhibiting the IDO
did not decrease the rise in inflammatory cytokines in response
to vaccination (O’Connor et al., 2009a). The product of IDO is
kynurenine. Systemic administration of kynurenine will induce
depression (O’Connor et al., 2009b) and kynurenine can pass
through blood brain barrier. In terms of potential ways that
kynurenine might impact neurotransmission, kynurenine does get
converted to quinolinic acid and kynurenic acid, both of which can
affect neurotransmitters signaling such as glutamate signaling and
dopamine signaling (Amori et al., 2009; Miller, 2009; Sublette et al.,
2011).
Another hypothesis links IDO activity to lower levels of sero-
tonin. Given IDO activity, tryptophan, the precursor to serotonin
gets depleted in plasma. Low serotonin has been suggested to
play a role in causing depressed behavior (Gal and Sherman,
1980; Miller, 2009; O’Connor et al., 2009a). Against the hypothesis
that IDO influences depressive behaviors by lowering tryptophan
levels are the findings that tryptophan depletion does not reli-
ably induce depression in all people, although those at risk for
depression may be more susceptible (Bell et al., 2001). More-
over, as previously mentioned, kynurenine alone, without any
reduction in tryptophan, can induce depression (O’Connor et al.,
2009b).
Another puzzling finding is that activation of the IDO enzyme
in macrophages in the periphery induces differentiation of T reg-
ulatory cells (Henry et al., 2008; Johnson et al., 2009), which as
discussed previously, are believed to counter depressive behav-
iors. At this point, the role of IDO in producing depression given
systemic inflammation awaits clarification.
The significance of neurogenesis and BDNF
In the literature on neuroprotection, the state of the microglia
and whether microglia foster or dampen the release of BDNF has
received a great deal of attention. In fact, administration of IL-1β,
an inflammatory cytokine, into the hippocampus will decrease the
expression of BDNF (Barrientos et al., 2004). The role of BDNF
and neurogenesis in depression has also been a focus of attention
in the animal literature on depression. The hypotheses that loss of
BDNF and downstream diminution of brain growth manifests as
depression and conversely that increasing BDNF prevents depres-
sion have been investigated. The findings suggest a more complex
reality than represented in the initial hypotheses.
Depressed animals and animals subjected to stress do exhibit
low levels of BDNF in the hippocampus. Animals subjected to
stress also exhibit less neurogenesis in the dentate gyrus of the
hippocampus (Lucassen et al., 2011). BDNF induces the growth
of dendrites from neurons so that they can make new connec-
tions with other neurons (Lucassen et al., 2011). While BDNF is
not necessary for neurogenesis, BDNF increases the survival of
new cells (Sairanen et al., 2005). Consistent with the possibility
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that BDNF is diminished in the hippocampus of depressed indi-
viduals, depressed individuals have lower hippocampal volume
(Bremner et al., 2000; Videbech and Ravnkilde, 2004). Moreover,
placing BDNF into the hippocampus (Shirayama et al., 2002), or
intracerebroventricular administration of IGF-1, which increases
BDNF levels (Carro et al., 2000; Cotman and Berchtold, 2002),
exert antidepressant effects in animals (Hoshaw et al., 2005).
Antidepressant drugs do increase neurogenesis in the dentate
gyrus of the hippocampus (Santarelli et al., 2003), although this
may be limited to adult males (Hodes et al., 2009). Research ask-
ing whether the efficacy of antidepressant drugs requires an animal
with the capacity for generating new neurons in the dentate gyrus
of the hippocampus has yielded inconsistent findings. Irradiation
of the subgenual zone of the dentate nucleus of the hippocampus,
blocked the efficacy of antidepressants in precluding the behav-
ioral effects of stress in one rat strain (Santarelli et al., 2003).
Consistent with this, Airan et al. (2007) found the irradiation of
the dentate gyrus precluded the efficacy of antidepressants both
on behavioral measures of depression and in increasing neuronal
signaling output from the dentate gyrus. However, subsequent
work in another rat species did not find that irradiation abro-
gated the efficacy of the antidepressant fluoxetine in exerting an
antidepressant effect nor did those animals displaying lower lev-
els of depressed behavior exhibit increased neurogenesis in the
dentate gyrus (Holick et al., 2008). Moreover, some drugs (for
example antagonists to melanin concentrating hormone) decrease
depressed behavior without influencing neurogenesis (Sahay and
Hen, 2007).
Others have looked at whether growth factors are required
for antidepressant efficacy. Monteggia et al. (2004) examined
the efficacy of antidepressants in blocking the emergence of
depressed behavior after exposure to stress. Without an intact
gene for expressing BDNF, antidepressants exhibited no efficacy in
abrogating the impact of chronic stress (Monteggia et al., 2004).
Nestler’s group has identified the mechanism through which
stress alters the expression of BDNF and the mechanism through
which antidepressants increase the expression of BDNF. When
an animal is subjected to a stressor such as uncontrollable foot-
shock or restraint stress, the BDNF gene is harder to express. Two
methyl groups are added to the histone 3 at lysine 27 in the pro-
moter region of the gene for BDNF making it difficult to express
the BDNF. Antidepressants do not reverse the effects of chronic
stress on the BDNF gene; rather, they affect BDNF expression
through another mechanism. Nestler has shown that antidepres-
sants decrease the expression of histone deacetylase 5 (HDAC5)
in the hippocampus in stressed mice. Histone deacetylases remove
acetyl groups from promoter sites so that a gene is less likely to
be used to transcribe mRNA for producing a protein (Tsankova
et al., 2006; Krishnan and Nestler, 2008). With a lesser amount of
a particular HDAC5 present in the hippocampus, the expression
of BDNF is increased (Tsankova et al., 2006). However, the story
on HDAC5 is complex. Mice with global reductions in HDAC5
are more vulnerable to social defeat and the impact of antidepres-
sants on HDAC5 levels is region specific. Contrary to decreasing
HDAC5 expression in the hippocampus, imipramine will increase
HDAC5 expression in the Nucleus Accumbens (Tsankova et al.,
2006; Krishnan and Nestler, 2008).
At least in some species, antidepressant drug efficacy seems
to require growth factors and the capacity for neurogenesis. The
previous findings raise the possibility that a lack of BDNF or a
lack of neurogenesis in the hippocampus might cause depression.
Researchers have investigated this hypothesis. To investigate these
questions researchers have used conditional knock outs. Using a
conditional knock outs, researchers can control the timing for the
loss of the capacity to express a particular protein. Through the use
of conditional knock outs, researchers know they are looking at the
impact of the loss of functional presence of the protein product of
the gene rather than the impact of the loss of the protein during
development.
Monteggia et al. (2007) created a conditional knock out mouse
for BDNF. Male BDNF knock outs were more hyperactive. Female
BDNF knockouts displayed deficits on a forced swim task consid-
ered to be a measure of depression and deficit sucrose preference,
a measure of anhedonia. Thus, in the Monteggia et al. study, loss
of BDNF in increasing depressive behavior is dependent upon
gender. Consistent with Monteggia et al.’s male knockouts, Ito
et al. (2011) found that their conditional knockout of BDNF in
the hippocampus, displayed increased levels of aggression toward
conspecifics and did not differ from controls on the forced swim
test, a commonly used measure of depression. Thus, the condi-
tional knock out studies fail to support the hypothesis that loss
of BDNF in male animals results in behavioral manifestations of
depression.
Other researchers have investigated whether blocking neuro-
genesis induces depression. Irradiating the hippocampus to block
neurogenesis does not increase the animals level of depression as
evidence by longer latency to feed in a novel situation or immobil-
ity on a forced swim test (Santarelli et al., 2003; Airan et al., 2007),
nor does blocking neurogenesis in the hippocampus increase the
animal’s level of distress as evidenced by failure to groom after
uncontrollable stress (Santarelli et al., 2003).
While impaired capacity of cell proliferation in the hippocam-
pus seems to be ruled out as a cause of depression at least under
baseline conditions, problems with cell division elsewhere in the
brain might play a causal role in producing behavioral depression.
Pharmacological destruction of astrocytes cells in the prefrontal
cortex (PFC) will induce depressed behavior in an animal. A simi-
lar reduction of astrocytes in the PFC occurs in animals exposed to
uncontrollable stress. Astrocyte cell death and behavioral signs of
depression co-occur whether the astrocyte cell death results from
exposure to uncontrollable stress or to a drug which is specifi-
cally toxic to astrocyte cells (Banasr and Duman, 2007). Astrocytes
do influence neurons. They are a major source of neurotrophins
in brain which seems to be induced by dopamine (Miklic et al.,
2004). Moreover, the loss of glial cells (both oligodendrocytes
and astrocytes) in the subgenual region of the anterior cingulate,
the dorsolateral PFC, the supragenual cingulate cortex, and the
orbitofrontal cortex, has emerged as marker for major depression
(Ongur et al., 1998; Rajkowska and Miguel-Hidalgo, 2007).
Location of BDNF expression determines the impact on behavior
Placing BDNF into the hippocampus of an animal will exert an
antidepressant effect on a forced swim test and on escape deficit
following exposure to inescapable shock (Shirayama et al., 2002).
Frontiers in Psychology | Psychology for Clinical Settings August 2012 | Volume 3 | Article 297 | 6
Littrell Inflammation
However, an opposite pattern is found in the Nucleus Accumbens.
High levels of expression of BDNF in the Nucleus Accumbens
released from neurons projecting from the Ventral Tegmental Area
will result in depressed behavior (Eisch et al., 2003). In terms of
the function of BDNF in the Nucleus Accumbens, Nestler and Car-
lezon (2006) postulate that expression of BDNF in the Nucleus
Accumbens is required for learning connections between exter-
nal stimuli and negative or positive valences. Thus, the impact of
BDNF on ameliorating depressive behaviors is brain area specific.
Summary
Thus far, it has been argued that inflammation in the brain
is sufficient to create behavioral depression. Investigators have
attempted to identify causal mechanisms through which inflam-
matory cytokines in brain result in depressed behavior. Dimin-
ished neurogenesis and/or reductions in growth factors such as
BDNF were raised as possible mediating factors of inflamma-
tory cytokines. Inflammation in brain does suppress neurogenesis
and the expression of BDNF in the hippocampus. However, given
that blocking neurogenesis in the hippocampus or preventing the
expression of BDNF fails to create depression, suggests that lack
of capacity for neurogenesis in the hippocampus is not sufficient
to cause depressed behavior. However, the possibility that inflam-
mation creates depression by blocking cell division in astrocytes
in the PFC remains a possibility.
THE HEALTH-PROMOTING PATHWAY
As previously discussed, when microglia are activated along an
inflammatory pathway, depression is observed. In addition to acti-
vation along an inflammatory pathway, microglia can also become
activated along several other pathways as well (Michelucci et al.,
2009; Derecki et al., 2011). Microglia can assume a form of activa-
tion through which they maintain the health of neurons (Butovsky
et al., 2006; Schwartz and Ziv, 2008b; Ekdahl et al., 2009; Kosloski
et al., 2010). When in the growth promoting mode, microglia
release Insulin-like growth factor-1 (IGF-1; Butovsky et al., 2005;
Ekdahl et al., 2009; Kosloski et al., 2010; Schwartz and Shechter,
2010a; Ron-Harel et al., 2011). IGF-1 slows inflammation and
decreases production of inflammatory cytokines (Pons and Torres-
Aleman, 2000; Venters et al., 2001; Park et al., 2011). In addition
to being anti-inflammatory, IGF-1 will induce neurons to release
BDNF (Carro et al., 2000; Cotman and Berchtold, 2002).
Activation of microglia along the inflammatory pathway versus
the growth promoting pathway are mutually inhibitory. TNF-α, an
inflammatory cytokine, is inversely correlated the release of IGF-
1 from microglia (Butovsky et al., 2006; Schwartz and Shechter,
2010b). IGF-1 can decrease NF-κB transcriptional activity in astro-
cytes and in TNF-α exposed cells (Pons and Torres-Aleman, 2000).
If exogenous IGF-1 is injected into the lateral ventricle along with
LPS, then there is less transcription of the genes associated with
an array of inflammatory factors including TNF-α, IL-1β, and
inducible nitric oxide synthase (iNOS; Park et al., 2011). Dantzer
et al. (1999) concomitantly, administered LPS and IGF-1 into the
intracerebroventricular area. The IGF-1 administration prevented
the emergence of sickness behavior, viz., immobility and reduced
exploration of a novel environment that otherwise occurs with
LPS administration (Dantzer et al., 1999).
Keeping microglia in a health-promoting state is important.
Neurons and astrocytes release factors such as fractalkine and
Jagged 1 to keep microglia in a quiescent state (Sestan et al., 1999;
Elyaman et al., 2007; Michelucci et al., 2009) and fractalkine will
downregulate microglia production of IL-1β in response to LPS
(Mizuno et al., 2003; Wynne et al., 2010). However, researchers
have also focused on the role of T cells in maintain brain health.
The interaction between T cells and the microglia
Schwartz and Ziv have focused on the role that T cells play in deter-
mining the behavior of microglia. Schwartz and Ziv (2008a) have
proposed that self-reactive T cells with receptors (TCRs) targeted
toward central nervous system (CNS) proteins are continually
playing a surveillance role. When activated in pro-neurogenesis
pathways, they maintain the health of the CNS. T cells, proba-
bly by influencing microglia, are vital to the brain’s repair after
stroke, for precluding a reduction in levels of BDNF following a
psychological stressor, for avoiding symptoms of post traumatic
stress disorder (PTSD) after psychological stress, for spatial learn-
ing, for neurogenesis stimulated by exercise (Cohen et al., 2006;
Ziv et al., 2006; Ziv and Schwartz, 2008a,b; Schwartz and Shechter,
2010a) and for capacity to detoxify reactive alpha-oxoaldehydes
(Ron-Harel et al., 2011). T cells are recruited subsequent to activ-
ity and/or stress (Schwartz et al., 2009) to the choroid plexus, the
meninges, and the Virchow–Robin spaces from which they are
able to influence the function of the microglia (Schwartz and Ziv,
2008b; Derecki et al., 2010; Schwartz and Shechter, 2010a,b). The
presence of T cells is required for the efficacy of environmental
manipulations, such as an enriched environment, to increase the
number of microglia releasing IGF-1 in the hippocampus (Ziv
et al., 2006; Ziv and Schwartz, 2008a,b; Schwartz and Shechter,
2010a,b). T cells must also be present to witness an increase in
IGF-1 in brain given physical activity (Schwartz and Shechter,
2010a).
Support for the importance of T cells in maintaining brain
health comes from studies in which all T cells or T cells with TCRs
specific for myelin basic protein have been eliminated. Mice that
are genetically engineered to lack T cells display severe inability to
learn. Replenishing T cells from normal mice into mice which lack
T cells can restore the ability to learn and reverse memory deficits
(Yirmiya and Goshen, 2011). The importance of T cells has also
been demonstrated for the capacity for resilience in the face of
stress. Given a stressor such as a predator odor, the expression of
ICAM-1 on endothelial cells lining blood vessels in the hippocam-
pus and epithelial cells in the choroid plexus increases to facilitate
and guide the migration of T cells, specific for brain proteins, into
the brain (Lewitus et al., 2008). When this fails to occur because
T cells specific for brain protein have been depleted, more behav-
ioral signs of distress are observed subsequent to stressor exposure
(Cohen et al., 2006).
Support for the importance of T cells specific to brain proteins
also comes from vaccination studies. Lewitus et al. (2008, 2009)
vaccinated animals with a protein found in the CNS, myelin basic
protein, but which had been altered to make the myelin basic pro-
tein less likely to induce a strong inflammatory response. Then the
animals were subjected to stressful conditions,which had been pre-
viously shown to induce depressive behavior as well as decreasing
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the level of BDNF in the hippocampus. After exposure to the
stressful conditions, the animals that had been vaccinated failed
to display decreased sucrose preference, a measure of anhedonia.
Moreover, the level of BDNF in the hippocampus remained at con-
trol levels. Consistent with higher levels of BDNF, the immunized
animals exhibited more neurogenesis in the hippocampus.
Which type of T cell?
In the Immunology literature, the identification of the various
paths along which T cells can be differentiated has been a vigorous
area of investigation. Five major types of T cells have been identi-
fied: Th1, T follicular helper cells, Th2, Th17, and Tregs. Two types
are germane here: Th2, which release IL-4, IL-3 and IL-13, and
Tregs (Mimran and Cohen, 2005; Murphy, 2012).
In the literature on the importance of T cells for the health of
the CNS, the topic of which type of T cells exert a salubrious effect
has not been a major focus of attention. However, given the various
roles that cells of the immune system can play in the brain raises
the issue of which particular cytokines and which particular type
of T cells promote brain health. Yirmiya and Goshen, commenting
on research by Derecki and others (Derecki et al., 2010; Yirmiya
and Goshen, 2011) noted that T cells present in meninges secret-
ing IL-4 were important for the capacity for learning. Presumably,
these cells were Th2 differentiated a non-inflammatory pathway.
Butovsky et al. (2006) showed that IL-4 induced microglia to
release IGF-1.
Some studies have asked about the impact of Tregs in influenc-
ing brain inflammation. Findings on the impact of Tregs have been
puzzling (Walsh and Kipnis, 2011). Kipnis et al. (2002) found that
Tregs, in the choroid plexus and meninges of the brain, dampen the
activity of other T cells so that less repair after injury occurs. When
Tregs are depleted, the animal exhibits stronger recovery after
crush injury of the optic nerve. Ziv et al. (2007) also found that
for promoting neurogenesis in brain after stroke, downregulat-
ing Tregs improves outcome. Moreover, subsequent work (Cohen
et al., 2006) showed that depleting an animal of all Tregs while
maintaining T cells specific for myelin basic protein precluded
signs of distress following exposure to the odor of a predator. In
some strains, the T effector cells and Tregs seem to cancel each
other’s protective effects (Kipnis et al., 2004).
There are other studies that suggest a salubrious role for T
cells in promoting brain health. Reynolds et al. (2007, 2009a,b)
have shown that co-culturing microglia with Tregs will attenu-
ate reactive oxidative species (ROS) and NF-κB transcriptional
activity subsequent to antigen exposure. Employing vaccination
as a mechanism for increasing a T regulatory response has also
been shown to yield neuroprotection. Researchers have vaccinated
animals with vasoactive intestinal peptide. Vasoactive intestinal
peptide elicits the differentiation of T cells into Tregs. Subse-
quently the animals were exposed to 1-methyl1-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), a chemical which will cause degen-
eration of neurons in the substantia nigra, creating symptoms of
Parkinson’s disease. The animals that had been vaccinated showed
resistance to the development of Parkinson’s disease (Kosloski
et al., 2010; Reynolds et al., 2010).
Whereas the previous studies, examined the impact of Tregs,
other studies have focused on identifying cytokines that exert a
neuroprotective effect. IL-10, a primary cytokine released by Tregs
and microglia, blocks neuronal apoptosis after injury (Zhou et al.,
2009). Interferon-γ (IFN-γ) and TGF-β also exert an influence
of microglia which drives neuroprotection (Kipnis et al., 2004).
Warner-Schmidt et al. (2011) argue that IFN-γ exerts an anti-
depressant effect by increasing levels of p11, a protein involved
in trafficking serotonin receptors to the cell membrane. Thus,
Warner-Schmidt et al. posited a role for IFN-γ beyond influencing
further inflammation. Given the inconsistencies in impact across
cytokines, it is important to replicate findings in various species to
determine whether findings are species specific.
What can be stated with confidence?
The mechanisms through which leukocytes play a role in main-
taining the health of the CNS is an area of intense research having
implications for degenerative diseases as well as mood disorders.
The interaction between T effector cells, Tregs, microglia, and
neurons requires more elucidation with recognition that find-
ings may not generalize across species or across strains within
a species (Walsh and Kipnis, 2011). The research on whether
Tregs are beneficial or not has been particularly inconsistent.
How Tregs impact brain inflammation may depend upon which
cells the Tregs are influencing. Future work may further identify
which types of T cells and which cytokines foster brain health
versus inflammatory responses. However, in the human litera-
ture, Tregs are prominently featured in work on the Hygiene
Hypothesis.
The hygiene hypothesis
The hygiene hypothesis attempts to explain why persons in the
third world have much lower rates of disorders associated with
inflammatory conditions: Parkinson’s disease, depression, anxiety
disorders, asthma, and inflammatory bowel disease. According to
the hygiene hypothesis, persons in the third world are exposed
to more pathogens, such as helminthes (parasitic worms) and
pathogens found in human feces, such as M. vaccae. These par-
ticular pathogens are good at eliciting the differentiation of T
cells into Tregs (Rook and Lowry, 2008, 2009; Raison et al.,
2010c). (As previously discussed, Tregs will dampen inflamma-
tion.) Downregulating inflammation systemically, will preclude
inflammatory cytokines in brain, thereby decreasing depression
and anxiety.
There are studies on how early life exposure to pathogens
impacts resilience or vulnerability to stress. Consistent with the
idea that early life exposure to pathogens is protective, Bilbo et al.
(2008) found that early life exposure to E. coli protected mice from
stress. As adults, when the mice were exposed to uncontrollable
shock, they displayed less diminution of social exploration and
less elevation in cortisol during the stressor. Contrary to the find-
ing that early life exposure to E. coli promotes resistance to stress,
exposure to particular bacteria for example, type A2/Singapore
influenza, may increase risk for later depression (Bale et al., 2010).
So does early life exposure to infection promote resilience or
vulnerability to stress? A testable hypothesis asserts that when a
pathogen elicits Tregs, the pathogen promotes resilience; whereas
when the pathogen fails to provoke Tregs, exposure promotes vul-
nerability. As findings accumulate identifying pathogens which
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are powerful in eliciting Tregs, some of the discrepancies in the
literature may be resolved.
Lowry has focused on those particular neuronal circuits that are
activated when a T regulatory response occurs. Subsequent to elic-
iting T regulatory response through vaccination with attenuated
M. vaccae, serotonergic neurons in the interfascicular dorsal raphe
were activated (Lowry et al., 2007). This resulted in a faster latency
to swim on the forced swim test, a laboratory measure of resilience
to depression. Inoculation with bacteria that failed to elicit a T
regulatory response did not have this effect. Elsewhere, Hale and
Lowry (2011) have differentiated the various serotonergic circuits
in the raphe. Some of these serotonergic neurons (in the caudal,
dorsal raphe) are involved in creating anxiety and learned helpless-
ness (Maier et al., 2006). The interfascicular dorsal raphe neurons
project to the medial PFC and are part of a feedback loop that
will downregulate the caudal dorsal raphe serotonergic neurons
to decrease learned helplessness. In terms of a mechanism for the
antidepressant effect of vaccination with M. vaccae, the M. vaccae
activate Tregs which activate the interfascicular dorsal raphe neu-
rons that suppress the anxiogenic/depressogenic circuitry (Lowry
et al., 2007, 2008). Lowry et al.’s research is important because
it raises the possibility that Tregs not only confer resilience to
stress by countering depressogenic inflammatory activation, but
also may confer resistance through a direct impact on neuronal
function. Lowry’s research suggests that Treg cytokines can induce
activity in interfascicular dorsal raphe neurons. The interfascicular
dorsal raphe neurons inhibit learned helpless behaviors.
SUMMARY
The case has been advanced that depression reflects an inflamma-
tory state in the brain. An inflammatory state in the brain can be
induced by inflammatory cytokines in the periphery or by psycho-
logical stressors. While some have focused on how brain inflamma-
tion results in manifestations of depression, others have examined
resilience. Microglia are the source of inflammatory cytokines,
associated with depressive behaviors, as well as the source of
IGF-1, associated with resilience. Events downstream of microglia
behavior have been investigated. Researchers have attempted to
identify which consequences of inflammatory cytokines result
in depressive behaviors. Inflammatory cytokines do decrease the
expression of growth factors (e.g., BDNF), which in turn impact
neurogenesis. However, findings fail to support the view that a
simple lack of BDNF or an incapacity for neurogenesis in the hip-
pocampus redounds in depression. Moreover, the impact of BDNF
varies according to the structure in the brain under observations.
Attempts to link cytokine levels in brain to a particular neuro-
transmitter’s function to explain depressive behaviors or resilience
have been made. Lowry’s work implied Treg anti-inflammatory
cytokines influence particular serotonergic neurons to yield stress
resilience. In fact, cytokines impact other neurotransmitter sys-
tems as well (Pace et al., 2012). Thus, how cytokines impact
neurotransmitters awaits further elucidation. The work on how
microglia can protect the brain and confer behavioral resilience to
stress has focused on identifying determinants of microglia behav-
ior, that is whether the microglia release inflammatory cytokines
or IGF-1. Questions regarding which particular cytokines, ema-
nating from specific T cell types, are most impactful in inducing
the microglia to be in a health and resilience promoting state have
been asked. Studies examining the role of Tregs has yielded some
contradictory findings. The future promises a more articulated
story on how the behavior of microglia, which is influenced by
specific types of T cells and the particular cytokines they release,
can result in depressive behavior or behavioral resilience.
Although the research does not yet offer an articulated mech-
anism for the ways in which inflammation mediates depressive
mood and behaviors and conversely how healthy microglia confer
resilience, it does appear that systemic inflammation is an influ-
ential link in the causal chain of depression. This, in turn, suggests
that we would be well advised to consider a variety of ways to
reduce systemic inflammation. The ways in which antidepressants
impact the immune system are now considered.
IMPACT OF ANTIDEPRESSANT DRUGS ON INFLAMMATION
Antidepressant drugs have become the standard treatment for peo-
ple suffering from depression, often being used even when the
patient is receiving psychological treatment. Given that inflam-
mation is involved in depression, possibly causally, it is useful to
examine the effects of antidepressant drugs on inflammatory state,
and also on whether the drugs can counteract conditions leading
to inflammation. Most of the studies that have been done on short
term influences of the drugs, in both animals and people. However,
it has become fairly standard for patients to remain on antidepres-
sants for years at a time. Given that these drugs have deleterious
side effects, it would be important to continue using them only as
long as they are effective. Therefore we examine the effects of anti-
depressants on inflammation in two sections: one on short term
use, and a separate one to see what can be discerned from studies
of people who have taken antidepressants for years.
SHORT TERM STUDIES
In the human literature, the efficacy of antidepressants has been
challenged (Kirsch, 2010). However, there is support for efficacy
in the animal literature. One causal factor in systemic inflam-
mation is stress. Studies have examined whether antidepressants
can abrogate the impact of stress. When animals are subjected to
uncontrollable stress, the extent of their distress can be gaged by
the reduction in their preference for sucrose consumption. Also,
they will fail to escape from an aversive stimulus. It turns out that
both of these stress responses can be abrogated by antidepressant
treatment (Bessa et al., 2009). Another way to produce stress in
animals is to put them in a novel environment. After exposure to
a novel environment, stress is manifested on a number of mea-
sures. Treatment with antidepressants will decrease immobility
in a forced swim test, will increase exploration in a novel envi-
ronment, and will preclude the decrement in food consumption
produced by a novel environment (Dulawa et al., 2004).
Questions about how selective serotonin reuptake inhibitors
(SSRIs) achieve their efficacy have been raised. Maes and col-
leagues, using human subjects, have shown that if SSRIs are
mixed with whole blood outside of the body, the production of
anti-inflammatory cytokines is increased while the production of
proinflammatory cytokines is decreased (Maes et al., 1999; Kubera
et al., 2001a). Obuchowicz et al. (2006) also showed in cultured
glial cells taken from animals, antidepressants will dampen the
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release of inflammatory cytokines in response to LPS. In other
studies, patients who were treated with antidepressants for a short
period of time have undergone blood draws and then cytokines
have been measured. Those persons taking antidepressants for 5–
8 weeks do exhibit lower levels of IL-6 levels in plasma (Sluzewska
et al., 1995; Basterzi et al., 2005); lower TNF-α levels (Lanquillon
et al., 2000; Tuglu et al., 2003); lower levels of monocytes and neu-
trophils in plasma (Seidel et al., 1996; Tuglu et al., 2003); higher
levels of IL-10 (Kubera et al., 2001b); and higher levels of Tregs
(Himmerich et al., 2010). Moreover, when whole blood from per-
sons taking antidepressants for 6 weeks are tested in response to a
mitogen stimulus, the ratio of IFN-γ/IL-10 is lower (Maes et al.,
1999; Kubera et al., 2001a). Thus, the case can be made that antide-
pressants, taken for several weeks, exert anti-inflammatory effects
as seen by specific changes cytokines, and thus offer a likely expla-
nation for the initial positive effects ascribed to antidepressant
drug use.
LONG-TERM STUDIES
There have been studies examining the long-term impact of anti-
depressants on systemic inflammation. Many of these studies
have examined the impact of antidepressants on phenomena that
are associated with increased systemic inflammation: diminished
heart rate variability, weight gain, metabolic syndrome, type II
diabetes, and atherosclerosis. These studies as well as the stud-
ies examining the impact of long-term antidepressant use on the
inflammatory marker of CRP are reviewed.
C-Reactive protein
C-Reactive protein is an acute phase protein released by the liver
in response to IL-6. It is considered to be a marker for sys-
temic inflammation (Blake and Ridker, 2002; Pearson et al., 2003).
Dawood et al. (2007) noted that treatment with an SSRI for
12 weeks significantly increased high sensitivity CRP. This finding
was consistent with Hamer et al.’s (2011) findings from two data
sets. In a data set of 4,584 research-participants from the White-
hall studies of British civil servants, long-term use (10 years) of
an antidepressant was associated with higher CRP after control-
ling for psychological distress. In a large sample of 8,131 Scottish
research-participants from another data set, an association was
noted between higher CRP levels and treatment with tricyclic anti-
depressants (TCAs) although no association was noted for those
treated with SSRIs. The duration of medication use and dosage
were not reported in the Scottish sample. However, Hamer et al.
noted that in the Whitehall study antidepressant use at only one
data point was not associated with CRP elevations. Thus, short
exposure to antidepressants probably is insufficient to raise CRP
levels.
Heart rate variability
Both the sympathetic and parasympathetic nervous systems inner-
vate lymph nodes, as well as the heart. In terms of innervation of
the heart, more parasympathetic control over the heart rate is
manifested as greater heart rate variability (Porges, 2007, 2009).
Greater heart rate variability is considered to reflect better coordi-
nation between breathing and heart function. Moreover, decreased
heart rate variability is a predictor of heart attacks and cardiovas-
cular disease (Hayano et al., 1990, 1996). In terms of innervation
of lymph nodes, acetylcholine from the post ganglion neuron of
the parasympathetic nervous system will inhibit release of TNF-α,
IL-1, IL-6, and IL-18 from macrophages. In the liver, greater vagal
tone will inhibit NF-κB activation and thus the release of acute
phase proteins (Pavlov and Tracey, 2005; Rosas-Ballina and Tracey,
2009). Thus, increasing vagal tone can be expected to decrease
systemic inflammation.
Several meta-analyses and studies of non-medically ill patients
treated with tricyclics for short periods of 6–16 weeks, have noted
a decrease in heart rate variability (Tulen et al., 1996; van Zyl et al.,
2008; Kemp et al., 2010). Results for SSRIs taken over a short period
of time have been inconsistent with several small N studies noting
a decrease in heart rate variability (Dawood et al., 2007) and oth-
ers finding no impact (Davidson et al., 2005; van Zyl et al., 2008;
Kemp et al., 2010).
The question of whether treatment with antidepressants makes
long-term outcomes less favorable requires investigation of how
antidepressants impact HRV when taken for over a year. In con-
trast to studies assessing short term impact of treatment, a study
by Licht et al. (2008) examined the impact of antidepressants
on persons with either remitted or current depression who were
followed for 8 years. Two measures of heart rate variability were
employed in the study: standard deviation of normal-to-normal
(SDNN) beats and respiratory sinus arrhythmias (RSA). The study
included 67 persons taking TCAs, 435 persons taking SSRIs, and
137 taking other antidepressants. There were 1,018 persons who
were depressed or had been depressed but were not taking med-
ications. The study also included 524 controls who had never been
depressed. Thus, there was a control group of persons who were
never depressed as well as persons who had been or were cur-
rently depressed broken down according to medication status. The
results were that those taking medications exhibited lower heart
rate variability when compared to never-depressed controls (for
SDNN, d = 0.207–0.849; for RSA, d = 0.413–0.862 across vari-
ous medications). Comparing those remitted depressed not on
medication or still depressed not taking medication did not dif-
fer from controls on SDNN beats and did not differ as greatly
from controls on RSA (d = 0.118). Licht et al. noted a dose–
response relationship between antidepressants and reduced HRV.
Licht et al. concluded that the association between lowered HRV
and depression (p. 1358) “appears to be mainly driven by the effect
of antidepressants.”
Weight gain
Obesity is considered to be an inflammatory state. Adipocytes are
capable of releasing IL-6 and TNF-α. It is estimated that 30% of the
IL-6 in circulation derives from adipose tissue. Moreover, omen-
tal fat tissue (fat around the abdomen) is populated by activated
macrophages releasing IL-6 (Mohamed-Ali et al., 1997; Hamer,
2007). Even in normal weight individuals, omental fat can be
inflammatory (Shelton and Miller, 2010). Weight reduction can
be expected to decrease systemic inflammation.
A meta-analysis of the impact of antidepressants on weight
gain suggested a strong effect for the TCAs and an effect for some
SSRIs (paroxetine) in studies examining long-term exposure to
antidepressants (over 6 months; Serretti and Mandelli, 2010). The
meta-analysis was consistent with an early review by Fava (2000)
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and a review by Deshmukh and Franco (2003) which concluded
that TCAs and paroxetine were particularly likely to be associated
with weight gain. A study by Kivimaki et al. (2010) found a corre-
lation between duration of treatment with antidepressants, both
TCAs and SSRIs, and greater weight gain. Moreover, a study of
persons treated with antidepressants for panic disorder for a year,
noted significant weight gain for all of the SSRIs (citalopram, flu-
oxetine, fluvoxamine, and paroxetine) used in the study (Dannon
et al., 2007).
Metabolic syndrome
As noted above, weight around the abdomen is inflammatory.
Weight around the abdomen is a component of metabolic syn-
drome. In a cross-sectional, large N study (25,315 subjects),
Raeder et al. (2006) found an association between abdominal
obesity, general obesity, higher cholesterol levels (components of
the metabolic syndrome), and the use of SSRIs after control-
ling for symptoms of anxiety and depression. Associations were
particularly pronounced among persons in their 40s who were
taking paroxetine and were absent in those taking citalopram. The
authors did not have data on duration of exposure, however, they
remarked that they expected metabolic syndrome to take some
time to develop.
Diabetes
Inflammatory cytokines create insulin resistance. Type II diabetes,
characterized by insulin resistance, is an inflammatory disease
(Dandona et al., 2011). Thus, an increase in type II diabetes might
be considered a proxy for an increase in systemic inflammation.
In a case-controlled study, persons who were all depressed at
entry into the study were followed for 2.8 years. Of those entering
the study, 2,243 persons developed diabetes during the follow-up
period. Those who developed diabetes were matched on age, gen-
der, and time in the study with 8,963 comparison subjects, who
had not developed diabetes. A comparison of long-term antide-
pressant users versus short term users yielded no difference on
their initial severity of depression. However, those developing dia-
betes were more likely to have been treated with antidepressants at
moderate to high doses for over 2 years prior to the onset of dia-
betes. The increased risks obtained for amitriptyline, fluvoxamine,
paroxetine, and venlafaxine (Andersohn et al., 2009).
Several other large-sample-size-studies have yielded findings
consistent with the hypothesis that long duration of exposure
antidepressants increase the risk of Type II diabetes. In a prospec-
tive study of 9,197 participants followed for 4.8 years, treatment
duration of over 6 months of an antidepressants (both the TCAs
and the SSRIs), doubled the risk of Type II diabetes. Duration of
exposure to the antidepressant was associated with elevated risk
for diabetes in both those with mild and moderate depression
(Kivimaki et al., 2010). In a third large N study (3,234 persons
with risk factors for diabetes), with a follow-up of 10 years, Rubin
et al. (2010) also found that continuous use of antidepressant use
increased the probability of developing diabetes. In those treated
with metformin, antidepressant use did not increase the risk of
diabetes development. The previously discussed study by Raeder
et al. (2006) also found that paroxetine was associated with higher
rates of diabetes.
Atherosclerosis
There is an association between major depression and heart dis-
ease (Frasure-Smith and Lespérance, 2006). Atherosclerosis, like
depression, is an inflammatory disease and inflammation con-
tributes to the calcification of the aorta (Kritharides et al., 2000).
In a study of heart patients after controlling for depressive symp-
toms, antidepressant use was found to be associated with greater
aorta calcification (Shah, 2011).
LONG-TERM EFFECTS OF ANTIDEPRESSANTS: A
MECHANISM FOR CREATING A CHRONIC COURSE
Previous sections have advanced the case for depression as an
inflammatory condition, with strong evidence for the conclusion
that inflammation is an important link in the cause of depression.
The evidence in this section points to the conclusion that short
term use of current antidepressant medications reduces inflam-
mation, and ameliorates depression. But additional data strongly
suggest that the positive effects are reversed with prolonged use.
That is, it is not merely the case that antidepressant medications
appear to lose their efficacy with prolonged use, but rather, they
promote reverse effects, increasing inflammation.
Contrasting data on the probability and frequency of depres-
sive relapses prior to the advent of pharmacological treatments to
the era after, Fava and Offidani (2011) along with an earlier paper
by Fava (2003) raised the possibility that antidepressants create a
chronic course in major depression. Littrell (1994) also contrasted
the duration of wellness intervals between episodes of depression
in persons before and after the advent of modern medications and
also noted that antidepressants shorten the duration of wellness
intervals. Fava and Offidani (2011) considered various possible
explanations for the mechanism through which antidepressants
contribute to chronicity of depression including tolerance, lower-
ing the brain’s threshold for mood fluctuations, and withdrawal
phenomenon from antidepressants. Another possibility is that
antidepressants, when taken for over a period of 6 months, increase
systemic inflammation such that depression becomes chronic. Evi-
dence suggests that when taken over years, antidepressants increase
systemic inflammation. Although increased inflammation fails
to obtain for particular classes of antidepressants (SSRIs versus
TCAs) on some measures,both classes of drug have been associated
with inflammation on at least one index. Thus, there is evidence
of increased inflammation for both classes of antidepressants.
The previously reviewed literature suggests that sustained expo-
sure to antidepressants for over a year is associated with more sys-
temic inflammation. The mechanisms through which long-term
use antidepressants might increase systemic inflammation have
not been investigated. Identifying these mechanisms is important
for future research. The other lesson emerging from this literature
is that evaluating drugs employing the usual 8 weeks of assessment
customary in drug trials is not sufficient for determining the effi-
cacy of pharmacological interventions. When the assumption is
that an individual will be exposed to a chemical over an extended
period, years rather than weeks are required.
WAY FORWARD
Research implicates inflammation as a proximal causal factor
in producing depressive symptoms. At present, psychological
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treatments for depression such as interpersonal therapy and Cog-
nitive Behavior Therapy have not been evaluated for their impact
on inflammation. In evaluating interventions, psychologists may
wish to include measures of inflammation, such as CRP, as depen-
dent measures. If psychological interventions decrease systemic
inflammation, then there would be evidence that psychologi-
cal treatments not only decrease levels of depression through a
direct pathway but also through the indirect pathway of impact on
systemic inflammation.
Systemic inflammation does contribute to depression. Over the
long run, antidepressants contribute to inflammation. If antide-
pressants either lose efficacy or contribute to inflammation in the
long run, other mechanisms for decreasing inflammation must
be relied upon for treating depression. The range of strategies for
improving mood is broadened by this research. Consumption of
omega-3 fatty acids (Kiecolt-Glaser,2010),adherence to a Mediter-
ranean diet (Dai et al., 2008; Sanchez-Villegas et al., 2009), and
consumption of curcumin (Aggarwal, 2011) lower inflammation
and lower the risk for depression. In animal work, curcumin has
been shown to exert antidepressant effects of similar magnitude
to antidepressant drugs (Wang et al., 2008). Interventions such
as exercise (Hamer, 2007), yoga (Bernardi et al., 2001; Kiecolt-
Glaser et al., 2010), meditation (Pace et al., 2009) have been shown
to dampen inflammation. Meditation (Pace et al., 2009), exer-
cise (Greenwood and Fleshner, 2008, 2011), and consumption of
omega-3s (Kiecolt-Glaser et al., 2011) have been demonstrated to
confer resilience to stress. Psychologists have a long tradition in
strengthening behavioral compliance and have the skills for assist-
ing individuals in adhering to life style changes. The recognition
that depression is an inflammatory disease ushers in a wealth of
new possibilities for treating and preventing mood disorders.
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